<?xml version="1.0" encoding="utf-8" standalone="yes" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Andrew Davies | Kaspar Rufibach, PhD</title>
    <link>https://www.kasparrufibach.ch/authors/andrew-davies/</link>
      <atom:link href="https://www.kasparrufibach.ch/authors/andrew-davies/index.xml" rel="self" type="application/rss+xml" />
    <description>Andrew Davies</description>
    <generator>Source Themes Academic (https://sourcethemes.com/academic/)</generator><language>en-us</language><lastBuildDate>Sun, 01 Jan 2017 00:00:00 +0000</lastBuildDate>
    <image>
      <url>https://www.kasparrufibach.ch/img/icon-192.png</url>
      <title>Andrew Davies</title>
      <link>https://www.kasparrufibach.ch/authors/andrew-davies/</link>
    </image>
    
    <item>
      <title>Obinutuzumab for the first-line treatment of follicular lymphoma</title>
      <link>https://www.kasparrufibach.ch/publication/2017-01-01_obinutuzumab_for_the/</link>
      <pubDate>Sun, 01 Jan 2017 00:00:00 +0000</pubDate>
      <guid>https://www.kasparrufibach.ch/publication/2017-01-01_obinutuzumab_for_the/</guid>
      <description></description>
    </item>
    
  </channel>
</rss>
